ReviewDrugs2006
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.
Review in Drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults.Clinical pharmacokinetics · 2024Pooled it
- Effectiveness of Psychobiotics in the Treatment of Psychiatric and Cognitive Disorders: A Systematic Review of Randomized Clinical Trials.Nutrients · 2024Pooled it
- Pharmacokinetic/Pharmacodynamic Optimization and Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Abdominal Sepsis: Current Evidence, Challenges, and Clinical Perspectives-A Narrative Review.Journal of clinical medicine · 2026Review
- Unveiling the Mechanisms of Bacterial Resistance and Countermeasures.Pathogens (Basel, Switzerland) · 2025Review
- Pharmacokinetics and Pharmacodynamics Evaluation of Amoxicillin AgainstPathogens (Basel, Switzerland) · 2024Article
- Efficacy of Continuous vs. Intermittent Administration of Cefepime in Adult ICU Patients with Gram-Negative Bacilli Bacteremia: A Randomized Double-Blind Clinical Study.Antibiotics (Basel, Switzerland) · 2024Article
- Surgical site infection in pediatric spinal fusion surgery revisited: outcome and risk factors after preventive bundle implementation.Perioperative care and operating room management · 2023Article
- The "Torment" of Surgical Antibiotic Prophylaxis among Surgeons.Antibiotics (Basel, Switzerland) · 2021Article
- Antimicrobial Resistance Surveillance and New Drug Development.Open forum infectious diseases · 2019Article
- Does size matter? Addressing pack size and antibiotic duration.Australian prescriber · 2019Article
- Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs.MedChemComm · 2018Article
- Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenPSensors (Basel, Switzerland) · 2018Article
- Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.Infection · 2016Article
- Strategies for combating bacterial biofilm infections.International journal of oral science · 2015Review
- Optimized antimicrobial dosing strategies: a survey of pediatric hospitals.Paediatric drugs · 2014Article
- In Vitro Antibiofilm Efficacies of Different Antibiotic Combinations with Zinc Sulfate against Pseudomonas aeruginosa Recovered from Hospitalized Patients with Urinary Tract Infection.Antibiotics (Basel, Switzerland) · 2014Article
- Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach.Antimicrobial agents and chemotherapy · 2012Article
- Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.Antimicrobial agents and chemotherapy · 2012Article
- Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider.Critical care (London, England) · 2011Article
- In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evolving antimicrobial resistance is of global concern. The impact of decreased susceptibility to current antibacterials coupled with the decline in the marketing of new agents with novel mechanisms of action places a tremendous burden on clinicians to appropriately use available agents. Optimising antibacterial dose administration through the use of pharmacodynamic principles can aid clinicians in accomplishing this task more effectively. Methods to achieve this include: continuous or prolonged infusion, or the use of smaller doses administered more frequently for the time-dependent beta-lactam agents; or higher, less frequent dose administration of the concentration-dependent aminoglycosides and fluoroquinolones. Pharmacodynamic breakpoints, which are predictive of clinical and/or microbiological success in the treatment of infection, have been determined for many classes of antibacterials, including the fluoroquinolones, aminoglycosides and beta-lactams. Although surpassing these values may predict efficacy, it may not prevent the development of resistance. Recent studies seek to determine the pharmacodynamic breakpoints that prevent the development of resistance. Numerous studies to this point have determined these values in fluoroquinolones in both Gram-positive and Gram-negative bacteria. However, among the other antibacterial classes, there is a lack of sufficient data. Additionally, a new term, the mutant prevention concentration, has been based on the concentrations above which resistance is unlikely to occur. Future work is needed to fully characterise these target concentrations that prevent resistance.
Indexed as
Identifiers
16398565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.